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Giving Hope Through Research
A search for novel treatments for Parkinson’s disease, depression  
and drug abuse
b y  J u l i e  O ’ C o n n o r
Parkinson’s disease affects approximately one percent of people older than 65 years of age. 
Nearly one million people in the United States have 
been diagnosed with Parkinson’s disease, a chronic 
and progressively debilitating disorder. This motor 
system disorder which causes trembling in hands, 
arms, legs, jaw and face; stiffness of the limbs 
and trunk; slowness of movement; and impaired 
balance and coordination, is the result of the loss of 
dopamine-producing brain cells. 
While there is great hope in Parkinson’s disease 
research, there is no cure. A variety of medications 
provide relief from the symptoms, including 
levodopa, also known as L-dopa, that converts into 
dopamine as it reaches nerve cells in the brain. 
Levodopa therapy often results in the emergence of 
motor complications and eventually patients may 
not respond to the drug. Multiple years of L-dopa 
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treatment can cause severe side effects and possible 
neurotoxicity leading to the withdrawal of use of 
the drug. 
But an answer to why Parkinson’s disease 
develops in some patients and a cure for it remains 
a mystery. “No ideal therapies are available for 
slowing the progression of the degeneration process 
and at the same time relieving symptomatic 
abnormalities associated with the disease,” said 
Aloke Dutta, Ph.D., professor of pharmaceutical 
sciences and medicinal chemistry in the Eugene 
Applebaum College of Pharmacy and Health 
Sciences at Wayne State University. 
Dr. Dutta aims to change this by developing a 
neuroprotective therapy that may slow down the 
degeneration process. By developing new drugs that 
focus on relieving motor dysfunction while at the 
same time introducing other properties that will 
reduce oxidative stress in the brain, Dr. Dutta hopes 
to promote survival of more dopamine neurons and 
at the same time provide symptomatic relief of  
the disease.  
Still early in their NIH-supported research, 
Dr. Dutta and his research team have developed 
some initial lead molecules with multifunctional 
activities which appear to exhibit some of the 
desired properties required for neuroprotection 
effects along with the property to alleviate motor 
dysfunction. Dr. Dutta and his interdisciplinary 
research team are collaborating with researchers at 
New York University School of Medicine and Baylor 
College of Medicine. Together they are combining 
drug discovery and computational chemistry along 
with in vitro and in vivo pharmacology, which 
ultimately will intensify development of such 
agents in the near future. 
Promising new antidepressant 
technology
Dr. Dutta is also addressing drawbacks in current 
antidepressant treatments. Major depression is a 
disorder posing significant health problems. After 
cardiovascular disease, depression is considered the 
second most debilitating disease in the world. “Drug 
therapies currently on the market for treatment of 
depression have many problems and shortcomings,” 
said Dr. Dutta. “A number of the therapies don’t 
work for a significant number of patients, and some 
treatments work at first, but later are ineffective.”  
According to Dr. Dutta, these treatments don’t 
address the dopamine component needed to 
interact with the relevant targets in the brain. 
Dr. Dutta and his research team along with 
collaborators from the New York University School 
of Medicine have discovered that by combining 
three monoamine transporters blocking activities 
into a single molecule, a new generation of 
antidepressants could be developed. One such 
lead polyfunctional molecule discovered in Dr. 
Dutta’s laboratory interacts with norepinephrine, 
serotonin and dopamine systems in the brain, and 
exhibited remarkable activity in preclinical in vivo 
antidepressant tests, indicating that it might possess 
a potent antidepressant activity. 
“One of our goals will be to study whether such 
novel triple uptake inhibitor molecules can produce 
more desirable therapeutic profiles as antidepressant 
agents compared to the current existing drugs 
and whether their chronic exposure might lead 
to the production of neurotrophic factors in the 
central nervous system via gene expression,” said 
Dr. Dutta. “This study has the potential to lead to 
other possible applications, such as treatment of 
obesity and neuropathic pain. This patent pending 
technology has great promise to make a difference 
in the lives of many,” he added. 
Finding a treatment for cocaine 
dependency
According to the 2003 National Survey of Drug 
Use and Health, over 2.1 million U.S. adults 
reported using cocaine within 30 days prior to the 
survey. Currently no medication is approved for 
clinics to treat this addiction. 
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“We believe a suitable treatment 
for such a devastating addiction 
will not only help people with 
overcoming such addictions, but 
also reduce a heavy economic 
burden of  our society.” 
— Dr. Aloke Dutta
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“The evidence from preclinical studies suggests 
that the reinforcing effect of cocaine that promotes 
its abuse is mostly mediated by blockade of the 
presynaptic dopamine transporter resulting in 
modulation of dopaminergic activity in the 
mesolimbic or meso-accumbens dopamine reward 
system of the brain,” said Dr. Dutta. With repeated 
use, cocaine can cause long-term changes in the 
brain, leading to addiction. Tolerance to the cocaine 
high often develops, causing users to increase the 
amount they use to intensify and prolong the 
euphoria, which often leads to an increased risk of 
adverse psychological or physiological effects. 
Dr. Dutta’s research in the field of drug abuse 
has been supported by NIH for a number of years. 
“Our effort to combat cocaine addiction is directed 
toward rational development of small molecules 
targeting the sites of interaction of cocaine in the 
brain that are responsible for its strong reinforcing 
effect,” said Dr. Dutta. Dr. Dutta’s research 
team, which includes collaborators from New 
York University School of Medicine and Virginia 
Commonwealth University, employs in vitro and 
in vivo behavioral pharmacology and molecular 
biology studies to understand the potential of 
new drugs as treatment agents. His team recently 
identified a promising lead compound, D-84, which 
interacts specifically with the dopamine transporter. 
Currently, this compound is undergoing extensive 
preclinical in vivo evaluation to explore its potential 
to treat cocaine and methamphetamine abuse. 
Several other molecules are also being investigated. 
“We believe a suitable treatment for such a 
devastating addiction will not only help people 
with overcoming such addictions, but also reduce a 
heavy economic burden of our society,” commented 
Dr. Dutta. 
About Dr. Aloke Dutta: Dr. Dutta received his B.S. 
in Chemistry and M.S. in Organic Chemistry from Calcutta 
University, Calcutta, India and his Ph.D. in Organic Chemistry 
from Ohio University. He joined Wayne State University 
in 1998. 
P
A
G
E
 2
5
✼
4
New Science, Vol. 17 [2009], Iss. 1, Art. 7
http://digitalcommons.wayne.edu/newscience/vol17/iss1/7
